Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease
- 1 January 2005
- journal article
- review article
- Published by Elsevier BV in The Lancet
- Vol. 365 (9454), 167-175
- https://doi.org/10.1016/s0140-6736(05)17708-3
Abstract
No abstract availableThis publication has 21 references indexed in Scilit:
- TheophyllineAmerican Journal of Respiratory and Critical Care Medicine, 2003
- Phosphodiesterase-4 Inhibitors in the Treatment of Inflammatory Lung DiseaseDrugs, 2003
- Low-dose fluticasone propionate compared with montelukast for first-line treatment of persistent asthma: A randomized clinical trialJournal of Allergy and Clinical Immunology, 2001
- Effect of Inhaled Triamcinolone on the Decline in Pulmonary Function in Chronic Obstructive Pulmonary DiseaseNew England Journal of Medicine, 2000
- Low-dose inhaled fluticasone propionate versus oral zafirlukast in the treatment of persistent asthmaJournal of Allergy and Clinical Immunology, 2000
- Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trialBMJ, 2000
- Immunosuppressive and anti-inflammatory effects of cyclic AMP phosphodiesterase (PDE) type 4 inhibitorsImmunopharmacology, 2000
- Long-Term Treatment with Inhaled Budesonide in Persons with Mild Chronic Obstructive Pulmonary Disease Who Continue SmokingNew England Journal of Medicine, 1999
- Oral Montelukast, Inhaled Beclomethasone, and Placebo for Chronic AsthmaAnnals of Internal Medicine, 1999
- Phosphodiesterase IsozymesAmerican Journal of Respiratory and Critical Care Medicine, 1998